Aripiprazole

Long-Acting Injectable Antipsychotics: A Practical Guide for Prescribers

Author: Flavio Guzman, MD Competing interests: none This article summarizes the most clinically relevant features of long-acting injectable antipsychotics (LAIs, previously known as depot antipsychotics). We discuss general concepts as well as key prescribing facts of individual agents. The guide also includes two new formulations: aripiprazole lauroxil (Aristada) and 3-month paliperidone palmitate (Invega Trinza). Advantages and disadvantages of long-acting antipsychotics…

Read More

Aripiprazole Lauroxil Extended-Release Injectable (ARISTADA)

By Flavio Guzman, MD Prescribing information highlights To be administered by intramuscular injection in the deltoid (441 mg dose only) or gluteal (441 mg, 662 mg or 882 mg) muscle by a healthcare professional. For patients naïve to aripiprazole, establish tolerability with oral aripiprazole prior to initiating treatment with ARISTADA. ARISTADA can be initiated at…

Read More

Aripiprazole for Schizophrenia

By Flavio Guzman, MD Aripiprazole (Abilify, BMS) is a second-generation antipsychotic approved in 2002 for the treatment of schizophrenia. Oral and intramuscular formulations are available. This page summarizes the most relevant papers on the use of aripiprazole for the management of schizophrenia. We have selected mostly review papers that focus on efficacy and tolerability of…

Read More

Aripiprazole for Mania

By Flavio Guzman, MD Aripiprazole is approved for the treatment of manic episodes in type I bipolar disorder. In this page you can find abstracts of review articles, guideline comments and controlled trials on the use of aripiprazole for the management of mania. Review Articles Aripiprazole: a review of its use in the management of…

Read More

Aripiprazole Indications: FDA-Approved and Off-Label Uses

Author: Flavio Guzman, MD. Aripiprazole is a second-generation (atypical) antipsychotic approved for the treatment of schizophrenia, bipolar disorder, depression and autism spectrum disorders. This article explores FDA-approved indications, dosing and evidence base for common off-label uses. FDA-approved indications Aripiprazole was originally approved in 2002 for the treatment of schizophrenia. Currently, the FDA has approved aripiprazole…

Read More
Aripiprazole Mechanism of Action

Mechanism of Action of Aripiprazole

By Flavio Guzman, MD. As with other drugs in psychopharmacology, the mechanism of action of aripiprazole in schizophrenia has not been fully elucidated. From a pharmacological perspective, aripiprazole is different to other antipsychotic agents, as it is the only approved antipsychotic that reduces dopaminergic neurotransmission through D2 partial agonism, not D2 antagonism. The following presentation…

Read More

Pharmacokinetics of Aripiprazole: Clinical Summary

By Flavio Guzman, MD. Formulations Tablets Orally disintegrating tablets Liquid formulation IM injection General pharmacokinetics and drug interactions Half-life aripiprazole: 75 hours dehydro-aripiprazole: 94 hours Elimination Mainly through hepatic metabolism involving two P450 enzymes: CYP3A4: dose adjustment might be needed in the presence of inhibitors or inducers. CYP2D6: dose adjustment might be needed in the…

Read More